Cerebral: Which Patient Profiles Should Avoid This Platform

What Is Cerebral and How Does It Work

Cerebral launched in 2020 as a subscription telehealth platform targeting mental health and ADHD. Patients pay a monthly fee, complete an online intake, and are matched with a prescriber or therapist. The model attracted millions of users quickly, driven partly by aggressive digital advertising.

Core Service Model

The company operates on an asynchronous and video-visit hybrid. Prescribers can issue diagnoses and write prescriptions without an in-person evaluation. That design is standard for many telehealth companies, but it created documented problems when applied to Schedule II and III controlled substances such as amphetamine salts and mixed amphetamines (Adderall) and stimulants like methylphenidate (Ritalin).

The FDA has published guidance on prescribing controlled substances via telemedicine, noting that federal law requires in-person evaluations for Schedule II drugs in most circumstances unless a specific DEA exception applies. Cerebral's prescribing practices around those rules became the central regulatory complaint.

Revenue Structure

Cerebral charges subscription fees plus optional therapy add-ons. A 2022 investigation found that the company's internal metrics rewarded prescriber productivity, with some reports suggesting that prescribers faced pressure to write more prescriptions per session. The DEA's 2022 investigation into Cerebral and co-occurring platforms examined whether stimulant prescriptions were being issued without adequate diagnostic rigor.

The DEA Investigation and DOJ Settlement

Federal scrutiny of Cerebral is not a rumor. It is documented, public, and specific.

DEA Scrutiny in 2022

In March 2022, Cerebral voluntarily paused prescribing of controlled substances for new patients. The company cited a review of its own practices as the reason, but this came directly after DEA subpoenas were issued to multiple telehealth platforms. The DEA's position on telemedicine prescribing of controlled substances is explicit: a valid prescription requires a legitimate medical purpose and a proper patient-practitioner relationship.

The DEA Diversion Control Division tracks telehealth-related prescription violations. Cerebral was named in congressional testimony and press coverage as one of the platforms under federal review.

DOJ Settlement

In 2024, Cerebral entered a settlement with the Department of Justice related to its prescribing practices. The agreement addressed allegations that the company had submitted false claims and facilitated improper prescribing. This settlement is publicly verifiable through the DOJ press release archive.

Patients should know that a settlement does not necessarily mean full resolution of the underlying structural problems. Current prescribing practices may differ from 2021 and 2022 operations, but institutional culture takes years to change.

Specific Patient Profiles That Should Avoid Cerebral

This is the section that matters most for clinical decision-making. Not every patient is a bad fit for Cerebral, but several profiles carry meaningfully elevated risk.

Profile 1: Patients With Complex or Treatment-Resistant Psychiatric Conditions

Cerebral is designed for mild-to-moderate presentations. Patients with treatment-resistant depression (defined by the FDA as failure of two adequate antidepressant trials), bipolar I disorder, schizoaffective disorder, or a history of psychiatric hospitalization need a level of clinical oversight that a subscription telehealth platform cannot provide.

The American Psychiatric Association's Practice Guidelines specify that patients with psychotic features, active mania, or recent suicidal ideation require coordinated care that includes regular in-person evaluation, labs, and often specialist consultation. A video-only model with high prescriber caseloads cannot meet those standards reliably.

Profile 2: Patients Seeking Schedule II Stimulants Without Prior Diagnosis

Adults requesting ADHD evaluation and stimulant prescriptions for the first time are the highest-risk group on this platform. The DSM-5-TR criteria for ADHD require evidence of symptoms present before age 12, impairment in two or more settings, and a differential diagnosis that rules out anxiety, mood disorders, and sleep disturbance. A 15-minute video intake cannot accomplish that rigorously.

Misdiagnosed ADHD is a real clinical problem. A 2023 JAMA Network Open study found that telehealth platforms showed higher rates of stimulant prescribing relative to in-person practices, raising questions about diagnostic accuracy. Schedule II stimulants carry real risks including cardiovascular effects, misuse potential, and drug interactions.

Profile 3: Patients With Active Suicidality or Recent Self-Harm

Cerebral's platform lacks the infrastructure to manage acute psychiatric emergencies. Patients with active suicidal ideation, a recent suicide attempt, or ongoing self-harm behaviors need immediate access to crisis services, inpatient evaluation capacity, and coordinated safety planning that meets Joint Commission standards.

The CDC reports that suicide is the 11th leading cause of death in the United States, with 47,646 deaths in 2022. Safe management of suicidal patients requires far more than a video visit and a prescription.

Profile 4: Children and Adolescents

Cerebral does not consistently serve minors across all states, but patients attempting to use the platform for children or teenagers with ADHD or anxiety should be cautious. Pediatric mental health requires different diagnostic frameworks, weight-based dosing considerations, school coordination, and family-systems involvement. The American Academy of Pediatrics guidelines on ADHD recommend a comprehensive evaluation process that a rapid telehealth intake does not replicate.

Profile 5: Patients Who Have Had Adverse Reactions to Psychiatric Medications

Anyone with a documented history of serotonin syndrome, neuroleptic malignant syndrome, severe SSRI discontinuation syndrome, or stimulant-induced psychosis needs a prescriber who can review a complete medication history, access prior records, and coordinate with other treating physicians. Cerebral's onboarding process may not capture that level of clinical complexity reliably.

The FDA MedWatch reporting system tracks serious adverse drug events. Patients with prior serious drug reactions should use that record when evaluating any new prescriber.

Profile 6: Patients in States Where Cerebral Has Reduced or Paused Services

Following the DEA investigation, Cerebral reduced its geographic footprint and paused certain controlled-substance prescribing in multiple states. A patient who starts care in a covered state and then moves may lose access to their prescriber and their prescription. Continuity of psychiatric care is not optional. The APA's telepsychiatry clinical guidelines specifically identify care continuity as a non-negotiable standard.

Documented Complaints and Consumer Reports

Cerebral's complaint record is publicly accessible and worth reviewing before enrollment.

BBB Complaints

The Better Business Bureau profile for Cerebral includes complaints about billing disputes, difficulty canceling subscriptions, and care quality concerns. The company is not BBB-accredited. Subscription-model telehealth companies generally receive higher complaint volumes related to billing than traditional practices, but the volume and pattern of Cerebral complaints specifically exceeded typical telehealth norms during its peak growth period in 2021 and 2022.

Former Employee Accounts

Former Cerebral employees have provided sworn testimony and on-record interviews describing pressure to prescribe controlled substances at high volumes. Some prescribers described caseloads that made thorough evaluation impossible. The New York Times and Wall Street Journal investigations from 2022 documented internal communications that described patients as "subscribers" in terms that conflated business metrics with clinical care.

State Medical Board Actions

Multiple state medical boards have reviewed Cerebral-affiliated prescribers. State board disciplinary actions are public records searchable through the Federation of State Medical Boards Physician Data Center. Patients can verify the license status of any Cerebral prescriber through their state board before beginning care.

Is Cerebral Legit

Yes, Cerebral is a legally operating telehealth company with real licensed clinicians. The question of legitimacy is more nuanced than a binary answer.

What "Legit" Means in Telehealth

LegitScript, the third-party certification body that FDA and major payment processors use to evaluate online pharmacies and healthcare providers, defines legitimate telehealth by whether a company requires valid prescriptions, employs licensed clinicians, and follows applicable federal and state laws. Cerebral has not consistently maintained LegitScript certification through its regulatory troubles.

The FDA's guidance on internet pharmacies and telehealth legitimacy lists several markers: a licensed pharmacist available to answer questions, state-licensed operation, and prescription requirements based on proper evaluation.

What the Record Shows

Cerebral employs real, licensed prescribers. It accepts real insurance. Prescriptions go to real pharmacies. By those measures, it is not a scam. The problems are clinical and structural, not fraudulent in the criminal sense for current operations. The DOJ settlement addressed past conduct.

Patients should treat Cerebral the way they would treat any medical provider: verify the prescriber's license, read the consent forms, confirm coverage before sharing payment information, and document all clinical interactions.

How Cerebral Compares to Clinical Standards for ADHD and Mental Health Care

The gap between what Cerebral offers and what evidence-based guidelines recommend is measurable.

ADHD Diagnostic Standards

CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) recommends that adult ADHD diagnosis include a clinical interview covering developmental history, rating scales from at least one collateral informant, and a differential diagnosis workup. A 2019 systematic review in The Lancet Psychiatry found that ADHD diagnosis requires careful exclusion of comorbid anxiety and mood disorders, which commonly mimic ADHD symptoms. A 15-minute video intake does not meet that bar.

Depression and Anxiety Screening

The PHQ-9 for depression and GAD-7 for anxiety are validated screening tools that Cerebral does use in its intake process. That is a point in its favor for mild-to-moderate presentations. For those specific conditions, the platform may provide adequate initial care. A 2022 Cochrane review of telehealth for depression found that synchronous video-based interventions can be as effective as in-person care for mild-to-moderate depression when adequate follow-up is provided.

Prescribing Quality Metrics

A 2023 study in JAMA Psychiatry examined telehealth prescribing patterns for stimulants from 2019 to 2022. The study found a 25% increase in stimulant prescriptions through telehealth channels, with the sharpest increases in young adults aged 18 to 35. The authors noted that "the rapid expansion of telehealth ADHD services has outpaced the development of quality metrics for appropriate diagnosis and prescribing," a concern directly applicable to platforms like Cerebral.

Red Flags to Watch for During Enrollment

If you are considering Cerebral or have already started the intake process, these signs suggest the encounter is below standard care.

No Collateral History

Any prescriber diagnosing ADHD without asking about childhood symptom history, requesting school records, or speaking with a family member is skipping required diagnostic steps per APA Practice Guidelines for ADHD.

Prescription Sent Before a Live Visit

If a prescription arrives before any video or phone contact with a licensed prescriber, that is a violation of federal telehealth prescribing standards. The DEA's telemedicine prescribing rules require an actual patient-practitioner relationship before any controlled substance prescription is valid.

No Safety Planning for Mood Symptoms

A platform treating depression or bipolar disorder without a documented safety plan for suicidal ideation does not meet SAMHSA's guidelines for outpatient mental health care.

Difficulty Reaching a Prescriber Between Visits

If the only contact point is a scheduling portal and urgent clinical questions go unanswered for 48 or more hours, that platform cannot manage psychiatric emergencies. The National Alliance on Mental Illness recommends that all mental health treatment include a clear crisis contact protocol.

Safer Alternatives for High-Risk Patient Profiles

Patients who do not fit the Cerebral model have real options.

For ADHD requiring stimulants, community mental health centers and psychiatry residency training clinics often offer sliding-scale fees with full diagnostic workups. The AAFP's telehealth resource page lists primary care telehealth providers who follow federal prescribing rules.

For complex depression or bipolar disorder, platforms like Talkiatry and Brightside explicitly require multi-visit diagnostic processes before prescribing and maintain prescriber continuity standards that Cerebral has historically struggled to match.

For crisis situations, the 988 Suicide and Crisis Lifeline is available 24 hours a day. The SAMHSA National Helpline at 1-800-662-4357 connects patients with local mental health services regardless of insurance status.

What Cerebral Does Reasonably Well

Balance requires noting where the platform performs adequately.

Cerebral's onboarding experience is accessible. For patients with mild depression or generalized anxiety who have no history of controlled substance prescriptions and no complex psychiatric comorbidities, the platform can connect them to an SSRI prescription and therapy faster than a typical outpatient psychiatry wait (often 6 to 12 weeks in urban areas, per NAMI data). The PHQ-9 and GAD-7 use in intake gives prescribers validated baseline severity data.

Insurance coverage is a real differentiator. Most direct-to-consumer mental health platforms operate cash-only. Cerebral's insurance contracting lowers the access barrier for insured patients who cannot afford $200 or more per session out of pocket.

Clinical Bottom Line

Cerebral is best suited for adults with mild-to-moderate depression or anxiety, no prior psychiatric hospitalization, no need for Schedule II stimulants, and no active safety concerns. Every other profile described in this article carries elevated risk that the platform's structure cannot adequately manage. Before enrolling, verify your prescriber's license through your state medical board via the FSMB directory, read Cerebral's cancellation policy in full, and confirm that your diagnosis does not require in-person evaluation under APA, AAP, or CHADD guidelines.